The Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration

Authors

  • A. F. Yusupov Republican Specialized Scientific and Practical Medical Center for Eye Microsurgery, Tashkent, Uzbekistan
  • M. Kh. Karimova Republican Specialized Scientific and Practical Medical Center for Eye Microsurgery, Tashkent, Uzbekistan
  • S. A. Djamalova Republican Specialized Scientific and Practical Medical Center for Eye Microsurgery, Tashkent, Uzbekistan
  • D. K. Makhkamova Republican Specialized Scientific and Practical Medical Center for Eye Microsurgery, Tashkent, Uzbekistan
  • S. I. Abdullaeva Republican Specialized Scientific and Practical Medical Center for Eye Microsurgery, Tashkent, Uzbekistan
  • M. A. Zakirkhodjaeva Republican Specialized Scientific and Practical Medical Center for Eye Microsurgery, Tashkent, Uzbekistan
  • Khodjaeva Zilola Republican Specialized Scientific and Practical Medical Center for Eye Microsurgery, Tashkent, Uzbekistan
  • D. A. Rakhimova Republican Specialized Scientific and Practical Medical Center for Eye Microsurgery, Tashkent, Uzbekistan

DOI:

https://doi.org/10.31288/oftalmolzh202432832

Keywords:

аge-related macular degeneration, neovascularization, optical coherence tomography, brolucizumab, intravitreal injection

Abstract

Aim. To evaluate the short-term efficacy of using a monoclonal antibody fragment (Brolucizumab) for treating neovascular age-related macular degeneration, depending on the morphometric parameters of the retina.

Methods: This study included 48 patients (60 eyes) diagnosed with neovascular age-related macular degeneration (nAMD). The observation period was 6 months. Brolucizumab was administered intravitreally at a dose of 6 mg (0.05 ml, 120 mg/ ml) once a month consistently for 3-4 months. Depending on the morphometric parameters, the retina patients were divided into three main groups.

Results: A pronounced clinical and morphological response was achieved after the first injection of Brolucizumab, and positive dynamics were observed throughout the entire observation period.

Conclusions: The use of the drug Brolucizumab significantly improves the visual functions of patients with neovascular AMD, as well as the morphological state of the retina in short-term follow-up, regardless of the initial morphometric characteristics of the retina, which allows not only to maintain but also to improve visual acuity and prevent blindness and visual disability in patients.

References

Nguyen QD, Das A, Do DV. et al. Brolucizumab: Evolution Through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127:963-976. https://doi.org/10.1016/j.ophtha.2019.12.031

Dugel PU, Koh A, Ogura Y. et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72-84. https://doi.org/10.1016/j.ophtha.2019.04.017

Dugel PU, Singh SR, Koh A. et al. HAWK and HARRIER: 96-Week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128:89-99. https://doi.org/10.1016/j.ophtha.2020.06.028

Colijn JM, Buitendijk GHS, Prokofyeva E, Alves D, Cachulo ML, Khawaja AP, et al. Prevalence of age-related macular degeneration in Europe: the past and the future. Ophthalmology. 2017;124:1753-63

Daien V, Finger RP, Talks JS, Mitchell P, Wong TY, Sakamoto T, et al. Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence. Br J Ophthalmol. 2021;105:1475-79 https://doi.org/10.1136/bjophthalmol-2020-317434

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31. https://doi.org/10.1056/NEJMoa054481

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-48. https://doi.org/10.1016/j.ophtha.2012.09.006

Mousa SA, Mousa SS. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs. 2010;24:183-94. https://doi.org/10.2165/11318550-000000000-00000

Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144-67. https://doi.org/10.1136/bjophthalmol-2014-305702

Research G, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388-98. https://doi.org/10.1016/j.ophtha.2012.03.053

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258-67. https://doi.org/10.1016/S0140-6736(13)61501-9

Pearce, I., Amoaku, W., Bailey, C. et al. The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice. Eye 36, 1725-1734 (2022). https://doi.org/10.1038/s41433-022-02008-3

Caroline R. Baumal, Torben Lykke Sørensen et al. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies. 2022.

Quan Dong Nguyen et al. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration Ophthalmology. Volume 127, Issue 7, July 2020, Pages 963-976 https://doi.org/10.1016/j.ophtha.2019.12.031

Downloads

Published

2024-07-02

How to Cite

1.
Yusupov AF, Karimova MK, Djamalova SA, Makhkamova DK, Abdullaeva SI, Zakirkhodjaeva MA, Khodjaeva ZA, Rakhimova DA. The Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration. J.ophthalmol. (Ukraine) [Internet]. 2024 Jul. 2 [cited 2024 Dec. 21];(3):28-32. Available from: https://ua.ozhurnal.com/index.php/files/article/view/130

Issue

No. 3 (2024): Journal of Ophthalmology (Ukraine)

Section

Clinical Ophthalmology

License

Copyright (c) 2024 Yusupov A. F., Karimova M. Kh., Djamalova Sh. A., Makhkamova D. K., Abdullaeva S. I., Zakirkhodjaeva M. A., Khodjaeva Z. A., Rakhimova D. A.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.

COPYRIGHT NOTICE

Authors who publish in this journal agree to the following terms:

  1. Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
  2. The copyright commencement date complies the publication date of the issue, where the article is included in.

DEPOSIT POLICY

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
  3. Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
  4. Archiving the pre-print (pre-refereeing manuscript version) not allowed.